Nephrotoxicity-What Do We Know and What Don't We Know?

被引:46
|
作者
Skinner, Roderick [1 ]
机构
[1] Royal Victoria Infirm, Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Paediat & Adolescent Oncol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
关键词
child; chemotherapy; drug toxicity; kidney; late sequelae; IFOSFAMIDE-INDUCED NEPHROTOXICITY; HIGH-DOSE IFOSFAMIDE; CISPLATIN NEPHROTOXICITY; RISK-FACTORS; RENAL TOXICITY; TUBULAR NEPHROTOXICITY; GLOMERULAR TOXICITY; SARCOMA PATIENTS; FANCONI SYNDROME; CANCER-PATIENTS;
D O I
10.1097/MPH.0b013e3181f8cac0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nephrotoxicity is the development of functional or structural kidney damage after exposure to one or more of a wide variety of drugs, other treatments or exogenous toxins, and may lead to a variety of functional consequences and structural lesions. Nephrotoxicity is important as it may occur in a substantial proportion of children treated with certain drugs and occasionally lead to severe renal impairment that may prevent the delivery of optimal anticancer treatment and/or reduce the quality of life of long-term survivors. This article describes what is currently known about nephrotoxicity occurring in children treated for malignancy by summarizing published information about the clinical characteristics and long-term outcome of, and the risk factors for the development of, ifosfamide and platinum-induced renal toxicity. Published guidelines for the evaluation and surveillance of nephrotoxicity, and the still incomplete understanding of its pathogenesis, are also outlined. Many gaps in our knowledge of nephrotoxicity are highlighted, including the lack of detailed knowledge about its overall incidence and very long-term impact, the nephrotoxic potential of new drugs, the efficacy of surveillance protocols, the relevance of proteinuria as a component of nephrotoxicity, and our current inability to reliably predict or prevent many episodes of nephrotoxicity.
引用
收藏
页码:128 / 134
页数:7
相关论文
共 50 条
  • [1] How Do We "Know" What We "Know?" And Change What We "Know?"
    Fosshage, James L.
    PSYCHOANALYTIC DIALOGUES, 2011, 21 (01) : 55 - 74
  • [2] Pediatric stroke: What do we know and what do we need to know?
    Lynch, JK
    Han, CJ
    SEMINARS IN NEUROLOGY, 2005, 25 (04) : 410 - 423
  • [3] Giving and using information: What we know and don't know
    Butow, Phyllis N.
    PATIENT EDUCATION AND COUNSELING, 2009, 77 (02) : 149 - 150
  • [4] Eating disorders and suicidality: what we know, what we don't know, and suggestions for future research
    Smith, April R.
    Zuromski, Kelly L.
    Dodd, Dorian R.
    CURRENT OPINION IN PSYCHOLOGY, 2018, 22 : 63 - 67
  • [5] Transmission of Ebola Viruses: What We Know and What We Do Not Know
    Osterholm, Michael T.
    Moore, Kristine A.
    Kelley, Nicholas S.
    Brosseau, Lisa M.
    Wong, Gary
    Murphy, Frederick A.
    Peters, Clarence J.
    LeDuc, James W.
    Russell, Phillip K.
    Van Herp, Michel
    Kapetshi, Jimmy
    Muyembe, Jean-Jacques T.
    Ilunga, Benoit Kebela
    Strong, James E.
    Grolla, Allen
    Wolz, Anja
    Kargbo, Brima
    Kargbo, David K.
    Formenty, Pierre
    Sanders, David Avram
    Kobinger, Gary P.
    MBIO, 2015, 6 (02):
  • [6] ECLS-associated infections in adults: what we know and what we don't yet know
    Abrams, Darryl
    Grasselli, Giacomo
    Schmidt, Matthieu
    Mueller, Thomas
    Brodie, Daniel
    INTENSIVE CARE MEDICINE, 2020, 46 (02) : 182 - 191
  • [7] What do we know about why women bleed and what do we not know?
    James, Andra H.
    James, Paula D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (02) : 315 - 322
  • [8] Hepatocellular adenoma: what we know, what we do not know, and why it matters
    Bioulac-Sage, Paulette
    Gouw, Annette S. H.
    Balabaud, Charles
    Sempoux, Christine
    HISTOPATHOLOGY, 2022, 80 (06) : 878 - 897
  • [9] The hip spine relationship-what we know and what we don't: a narrative review
    McCurdy, Michael
    Lee, Yunsoo
    DiNicola, Gino
    Ku, Albert
    Vaccaro, Alexander R.
    Hilibrand, Alan S.
    Schroeder, Gregory D.
    Kepler, Christopher K.
    Lambrechts, Mark J.
    AME MEDICAL JOURNAL, 2024, 9
  • [10] Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know
    Raben, D
    Helfrich, B
    Ciardiello, F
    Bunn, PA
    LUNG CANCER, 2003, 41 : S15 - S22